Professional
Added to YB: 2024-10-22
Pitch date: 2024-09-30
INSM [bullish]
Insmed Incorporated
+169.88%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Market Cap
$41.2B
Pitch Price
$73.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-42.82
P/E
-31.07
EV/Sales
90.08
Sector
Biotechnology
Category
growth
Show full summary:
Baron Health Care Fund New Position: Insmed Incorporated
INSM: 3 lead drugs w/ $8B+ peak sales potential. Brensocatib: game-changing NCFBE data (20% exacerbation reduction, improved lung function). 500K US patients, $5B+ market. Also promising for chronic rhinosinusitis ($1B+). Arikayce for MAC lung disease. TPIP for PAH/PH-ILD. Huge upside potential.
Read full article (1 min)